Influence of Goldenseal Root on the Pharmacokinetics of Indinavir

Journal of Clinical Pharmacology

Volumn 43, Issue 11, 2003, Pages 1283-1288

  Sandhu, Ranjeev S ^a   Prescilla, Randy P ^b   Simonelli, Thomas M ^a   Edwards, David J ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug interactions; Goldenseal root; Herbal medicine; Indinavir

Indexed keywords

CYP3A PROTEIN, HUMAN; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; GOLDENSEAL ROOT; INDINAVIR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD; BLOOD SAMPLING; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG INTERACTION; DRUG SAFETY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; HYDRASTIS; MALE; METABOLISM; NORMAL HUMAN; PHYSIOLOGY; PLANT ROOT; STATISTICAL SIGNIFICANCE;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; HYDRASTIS; INDINAVIR; MALE; MIDDLE AGED; PLANT ROOTS;

EID: 0142072045     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003258660     Document Type: Article

References (25)

1. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al: Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998;280:1569-1575.
2. Fairfield KM, Eisenberg DM, Davis RB, Libman H, Phillips RS: Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. Arch Intern Med 1998;158:2257-2264.
3. Hung OL, Shih RD, Chiang WK, Nelson LS, Hoffman RS, Goldfrank LR: Herbal preparation use among urban emergency department patients. Acad Emerg Med 1997;4:209-213.
4. Rehman J, Dillow JM, Carter SM, Chou J, Le B, Maisel AS, et al: Increased production of antigen-specific immunoglobulins G and M following in vivo treatment with the medicinal plants Echinacea angustifolia and Hydrastis canadensis. Immunol Lett 1999;68:391-395.
5. Abourashed EA, Khan IA: High-performance liquid chromatography determination of hydrastine and berberine in dietary supplements containing goldenseal. J Pharm Sci 2001;90:817-822.
6. Piscitelli SC, Burnstein AH, Welden N, Gallicano KD, Falloon J: The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002;34:234-238.
7. Piscitelli SC, Burnstein AH, Chaitt D, Alfaro RM, Falloon J: Indinavir concentrations and St. John's wort. Lancet 2000;355;547-548.
8. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G: Acute heart transplant rejection due to Saint John's wort. Lancet 2000;355:548-549.
9. Barone GW, Gurley BJ, Ketel BL, Abul-Ezz SR: Herbal supplements: a potential for drug interactions in transplant patients. Transplantation 2001;71:239-241.
10. Johne A, Brockmoller J, Bauer S, Maurer A, Landheinrich M, Roots I: Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338-345.
11. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, et al: Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001;70:518-524.
12. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P: St. John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002;54:349-356.
13. Dürr D, Steiger B, Kullak-Ublick GA, et al: St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68:598-604.
14. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT: An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7:273-282.
15. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Bocker RH, Beckurts KT, Lang W, et al: Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 2000;86:250-256.
16. Piscitelli SC, Formentini E, Burnstein AH, Alfaro R, Jagannatha S, Falloon J: Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacother 2002;22:551-556.
17. Jellin JM (ed.): Pharmacist's Letter/Prescriber's Letter Natural Medicines Comprehensive Database. 4th ed. Stockton, CA: Therapeutic Research Facility, 2002.
18. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA: Recent patterns of medication use in the ambulatory adult population of the United States: the Slone Survey. JAMA 2002;287:337-344.
19. Zou L, Harkey MR, Henderson GL: Effect of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002 Aug 16;71(13):1579-1589.
20. Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH: Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 1996;24:307-314.
21. Edwards DJ, Draper EJ: Variations in alkaloid content of herbal products containing goldenseal. JAPhA 2003;43:419-423.
22. Goldenseal (Hydrastis canadensis), in: Bratman S, Girman AM (eds.), Mosby's Handbook of Herbs and Supplements and Their Therapeutic Uses. St. Louis, MO: Mosby, 2003;624-627.
23. Ducharme MP, Warbasse LH, Edwards DJ: Disposition of intravenous and oral cyclosporine following administration with grapefruit juice. Clin Pharmacol Ther 1995;57:485-491.
24. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, et al: Mechanisms of enhanced oral bioavailability of CYP3A4 substrates by grapefruit constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997;25:1228-1233.
25. Penzak SR, Acosta EP, Turner M, Edwards DJ, Hon YY, Desai HD, et al: Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. J Clin Pharmacol 2002;42:1165-1170.